Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insmed Inc (INSM)

Insmed Inc (INSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,507,688
  • Shares Outstanding, K 213,273
  • Annual Sales, $ 363,710 K
  • Annual Income, $ -913,770 K
  • EBIT $ -1,152 M
  • EBITDA $ -1,132 M
  • 60-Month Beta 1.01
  • Price/Sales 120.23
  • Price/Cash Flow N/A
  • Price/Book 46.25

Options Overview Details

View History
  • Implied Volatility 66.61% (+1.08%)
  • Historical Volatility 49.70%
  • IV Percentile 84%
  • IV Rank 56.26%
  • IV High 92.41% on 04/10/25
  • IV Low 33.42% on 09/11/25
  • Expected Move (DTE 13) 14.59 (7.15%)
  • Put/Call Vol Ratio 2.21
  • Today's Volume 1,895
  • Volume Avg (30-Day) 2,211
  • Put/Call OI Ratio 1.05
  • Today's Open Interest 82,939
  • Open Int (30-Day) 99,345
  • Expected Range 189.41 to 218.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.39
  • Number of Estimates 8
  • High Estimate -1.08
  • Low Estimate -1.86
  • Prior Year -1.32
  • Growth Rate Est. (year over year) -5.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
182.53 +11.76%
on 11/07/25
212.75 -4.11%
on 12/02/25
+17.12 (+9.16%)
since 11/05/25
3-Month
134.01 +52.23%
on 09/26/25
212.75 -4.11%
on 12/02/25
+58.90 (+40.59%)
since 09/05/25
52-Week
60.40 +237.75%
on 04/09/25
212.75 -4.11%
on 12/02/25
+128.67 (+170.81%)
since 12/05/24

Most Recent Stories

More News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

INSM : 204.00 (-0.51%)
European Commission Approves BRINSUPRIâ„¢ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage   —

INSM : 204.00 (-0.51%)
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

More than 1,200 employees across the U.S., Europe, and Japan unite to support multiple organizations during annual company-wide day of service

INSM : 204.00 (-0.51%)
The Biotech Boom Gets a Trading Tool: How Direxion's Titans ETF Gives Access to the Sector's Top Performers

Amid the biotechnology sector's transformative era the Direxion Daily Biotech Top 5 Bull 2X ETF ($TBXU) offers traders a new, single-trade solution to gain 2X daily leveraged exposure to an e

ALNY : 458.12 (-1.55%)
EXEL : 44.36 (-0.02%)
GILD : 121.22 (-1.14%)
INSM : 204.00 (-0.51%)
UTHR : 489.31 (+1.08%)
Insmed To Present at November and December 2025 Investor Conferences

BRIDGEWATER, N.J. , Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

INSM : 204.00 (-0.51%)
Insmed: Q3 Earnings Snapshot

Insmed: Q3 Earnings Snapshot

INSM : 204.00 (-0.51%)
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

—BRINSUPRI ™   (brensocatib ) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted...

INSM : 204.00 (-0.51%)
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

—Insmed Leads  Science  Top Employers List for Fifth Year in a Row—

INSM : 204.00 (-0.51%)
CHMP Recommends EU Approval of BRINSUPRIâ„¢ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic Inflammation...

INSM : 204.00 (-0.51%)
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker—

INSM : 204.00 (-0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas...

See More

Key Turning Points

3rd Resistance Point 209.39
2nd Resistance Point 207.97
1st Resistance Point 205.99
Last Price 204.00
1st Support Level 202.58
2nd Support Level 201.16
3rd Support Level 199.18

See More

52-Week High 212.75
Last Price 204.00
Fibonacci 61.8% 154.55
Fibonacci 50% 136.57
Fibonacci 38.2% 118.60
52-Week Low 60.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar